<?xml version="1.0" ?>
<TimeML xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://timeml.org/timeMLdocs/TimeML_1.2.1.xsd">

<DOCID>695196472375</DOCID>

<DCT><TIMEX3 tid="t0" type="DATE" value="20170129" temporalFunction="false" functionInDocument="CREATION_TIME">January 29, 2017</TIMEX3></DCT>

<TITLE>EpiPen competitor to launch in February</TITLE>


<TEXT>
By A major competitor to EpiPen, the lifesaving allergy injection that has become the latest flashpoint in the debate over high drug prices, will <EVENT eid="e1" class="OCCURRENCE">launch</EVENT> on <TIMEX3 tid="t1" type="DURATION" value="PXD">Valentine's Day</TIMEX3> at a list price of $360 for a two-pack, the company Kalo <EVENT eid="e2" class="OCCURRENCE">announced</EVENT> on <TIMEX3 tid="t2" type="DATE" value="2017-01-26">Thursday</TIMEX3>. 
 
For <TIMEX3 tid="t3" type="DURATION" value="PXY">years</TIMEX3>, pharmaceutical company Mylan <EVENT eid="e3" class="OCCURRENCE">hiked</EVENT> the price on EpiPen  to $609 for a two-pack, <EVENT eid="e4" class="OCCURRENCE">enjoying</EVENT> a near monopoly on the growing allergy injection market. 
 
The practice <EVENT eid="e5" class="I_ACTION">catapulted</EVENT> the company into the crosshairs of politicians. Mylan's chief executive, Heather Bresch, <EVENT eid="e6" class="OCCURRENCE">found</EVENT> herself following in the footsteps of another pharmaceutical executive who <EVENT eid="e7" class="OCCURRENCE">engaged</EVENT> in a massive price hike, Martin Shkreli, at a Congressional <EVENT eid="e8" class="OCCURRENCE">hearing</EVENT> <TIMEX3 tid="t4" type="DATE" value="2016">last year</TIMEX3>. 
 
Mylan has <EVENT eid="e9" class="REPORTING">faced</EVENT> competitors before  <EVENT eid="e10" class="OCCURRENCE">including</EVENT> from the Auvi-Q before it was <EVENT eid="e11" class="OCCURRENCE">recalled</EVENT> from the market. But EpiPen's market dominance and familiarity to patients and doctors, as well as by various issues with its competitors, <EVENT eid="e12" class="REPORTING">meant</EVENT> that Mylan has been able to <EVENT eid="e13" class="OCCURRENCE">dominate</EVENT> the epinephrine auto-injector space. 
 
Now, EpiPen will <EVENT eid="e14" class="OCCURRENCE">go</EVENT> head-to-head with Auvi-Q and with the authorized generic of another auto-injector called Adrenaclick. <TIMEX3 tid="t5" type="DATE" value="2017-W04">Last week</TIMEX3>, CVS Health <EVENT eid="e15" class="REPORTING">said</EVENT> it would <EVENT eid="e16" class="OCCURRENCE">offer</EVENT> a two-pack of the generic version of Adrenaclick for $110. 
 
Mylan is <EVENT eid="e17" class="OCCURRENCE">readying</EVENT> itself for competition; it <EVENT eid="e18" class="REPORTING">launched</EVENT> an authorized generic of EpiPen <TIMEX3 tid="t6" type="DATE" value="2016">late last year</TIMEX3>, at half the list price  $300 for a two-pack. 
 
The list prices for these three products are all over the map: the Auvi-Q, which comes with a voice that talks patients through how to administer the injection, is <EVENT eid="e19" class="OCCURRENCE">priced</EVENT> at a slight premium to Mylan's generic EpiPen, which is further undercut by the CVS price for Adrenaclick's generic. 
 
But the list price doesn't <EVENT eid="e20" class="I_STATE">reflect</EVENT> what insurers <EVENT eid="e21" class="OCCURRENCE">pay</EVENT> because they <EVENT eid="e22" class="OCCURRENCE">negotiate</EVENT> secret rebates and discounts. It also doesn't <EVENT eid="e23" class="OCCURRENCE">reflect</EVENT> what patients generally <EVENT eid="e24" class="OCCURRENCE">pay</EVENT>, because insurance often passes through only part of the cost, through a co-pay or co-insurance. The <EVENT eid="e25" class="OCCURRENCE">growth</EVENT> in high deductible plans, in which patients are on the hook for the full cost of a drug until they <EVENT eid="e26" class="OCCURRENCE">hit</EVENT> a dollar limit, is <EVENT eid="e27" class="I_STATE">thought</EVENT> to have <EVENT eid="e28" class="I_ACTION">helped</EVENT> spur public <EVENT eid="e29" class="OCCURRENCE">outrage</EVENT> about EpiPen because consumers were increasingly <EVENT eid="e30" class="I_STATE">exposed</EVENT> to the escalating list price. 
 
The three companies are <EVENT eid="e31" class="OCCURRENCE">offering</EVENT> various kinds of coupons and patient affordability programs to <EVENT eid="e32" class="OCCURRENCE">defray</EVENT> the cost to consumers even further. Those programs <EVENT eid="e33" class="OCCURRENCE">reveal</EVENT> the varied patchwork that makes drugs affordable. 
 
For example, the Auvi-Q will be free to patients with commercial insurance  even if they have a high deductible plan, <EVENT eid="e34" class="REPORTING">according</EVENT> to Kalo. In addition to <EVENT eid="e35" class="OCCURRENCE">offering</EVENT> a $110 cash price at CVS for the Adrenaclick generic, the company Impax Laboratories is <EVENT eid="e36" class="OCCURRENCE">offering</EVENT> a $100 coupon. Mylan is <EVENT eid="e37" class="OCCURRENCE">offering</EVENT> a $25 coupon off out of pocket costs for its authorized generic. Coupons cannot be <EVENT eid="e38" class="OCCURRENCE">used</EVENT> by people with government insurance. 
 
In a broader sense, these options will <EVENT eid="e39" class="OCCURRENCE">give</EVENT> insurers more leverage when <EVENT eid="e40" class="I_ACTION">trying</EVENT> to <EVENT eid="e41" class="OCCURRENCE">negotiate</EVENT> the price of the <EVENT eid="e42" class="OCCURRENCE">medication</EVENT>. Insurers and the companies they <EVENT eid="e43" class="I_STATE">hire</EVENT> to <EVENT eid="e44" class="OCCURRENCE">negotiate</EVENT> on their behalf  pharmacy benefit managers  <EVENT eid="e45" class="OCCURRENCE">use</EVENT> competition and the threat of excluding a product altogether to wring deeper discounts. 
 
The insurer Cigna <EVENT eid="e46" class="REPORTING">announced</EVENT> <TIMEX3 tid="t7" type="DATE" value="2017-01">this month</TIMEX3> that it would <EVENT eid="e47" class="OCCURRENCE">cover</EVENT> only the generic versions of EpiPen and Adrenaclick. 
 
What <EVENT eid="e48" class="STATE">remains</EVENT> to be <EVENT eid="e49" class="PERCEPTION">seen</EVENT>, however, is whether savings insurers get from the increased negotiating clout are passed on to customers through reduced copays or, ultimately, lower premiums. What the EpiPen maelstrom <EVENT eid="e50" class="OCCURRENCE">laid</EVENT> bare, in part, was the complexity of drug pricing and the fact that many middlemen industries can also <EVENT eid="e51" class="OCCURRENCE">benefit</EVENT> from high drug prices.
</TEXT>


<MAKEINSTANCE eiid="ie49" eventID="e49" pos="VERB" tense="PASTPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie44" eventID="e44" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie39" eventID="e39" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="WOULD" />
<MAKEINSTANCE eiid="ie38" eventID="e38" pos="VERB" tense="FUTURE" aspect="PROGRESSIVE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie19" eventID="e19" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie18" eventID="e18" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie35" eventID="e35" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie34" eventID="e34" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie33" eventID="e33" pos="UNKNOWN" tense="PRESENT" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie32" eventID="e32" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie31" eventID="e31" pos="VERB" tense="PRESENT" aspect="PROGRESSIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie30" eventID="e30" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie11" eventID="e11" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie10" eventID="e10" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie13" eventID="e13" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie12" eventID="e12" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie15" eventID="e15" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie14" eventID="e14" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie17" eventID="e17" pos="VERB" tense="PRESENT" aspect="PROGRESSIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie16" eventID="e16" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie42" eventID="e42" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie51" eventID="e51" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie50" eventID="e50" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie37" eventID="e37" pos="VERB" tense="PRESENT" aspect="PROGRESSIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie36" eventID="e36" pos="VERB" tense="PRESENT" aspect="PROGRESSIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie40" eventID="e40" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie43" eventID="e43" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie41" eventID="e41" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie9" eventID="e9" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie8" eventID="e8" pos="NOUN" tense="NONE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie5" eventID="e5" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie4" eventID="e4" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie7" eventID="e7" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie6" eventID="e6" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie1" eventID="e1" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie3" eventID="e3" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie2" eventID="e2" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie24" eventID="e24" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie25" eventID="e25" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie26" eventID="e26" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie27" eventID="e27" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie20" eventID="e20" pos="VERB" tense="PRESENT" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie21" eventID="e21" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie22" eventID="e22" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie23" eventID="e23" pos="VERB" tense="PRESENT" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie46" eventID="e46" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie45" eventID="e45" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie28" eventID="e28" pos="VERB" tense="PASTPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie29" eventID="e29" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie47" eventID="e47" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie48" eventID="e48" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />

<TLINK lid="TL1" eventInstanceID="ie18" relatedToTime="t6" relType="IS_INCLUDED" />
<TLINK lid="TL5" eventInstanceID="ie2" relatedToTime="t2" relType="IS_INCLUDED" />
<TLINK lid="TL10" timeID="t7" relatedToEventInstance="ie46" relType="INCLUDES" />
<TLINK lid="TL9" timeID="t5" relatedToEventInstance="ie15" relType="INCLUDES" />
<TLINK lid="TL0" eventInstanceID="ie39" relatedToEventInstance="ie40" relType="DURING" />
<TLINK lid="TL6" eventInstanceID="ie46" relatedToTime="t7" relType="IS_INCLUDED" />
<TLINK lid="TL3" eventInstanceID="ie40" relatedToEventInstance="ie39" relType="SIMULTANEOUS" />
<TLINK lid="TL8" timeID="t2" relatedToEventInstance="ie2" relType="INCLUDES" />
<TLINK lid="TL7" eventInstanceID="ie28" relatedToEventInstance="ie30" relType="SIMULTANEOUS" />
<TLINK lid="TL2" eventInstanceID="ie15" relatedToTime="t5" relType="IS_INCLUDED" />
<TLINK lid="TL4" eventInstanceID="ie8" relatedToTime="t4" relType="IS_INCLUDED" />
</TimeML>
